Pictured: Macrophage & Tumor Cells
Feature
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, May 1, 2014

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

Pictured: Susan Prockop & Lucas T.
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Thursday, March 6, 2014

Memorial Sloan Kettering physician-scientists have prevented a dangerous complication of stem cell transplantation using immune cells donated from a third party.

Pictured: Marcel van den Brink & Robert Jenq
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, March 3, 2014

Research suggests that the presence of a type of bacteria called Blautia, which occurs naturally in the body, may prevent graft-versus-host disease, a potentially fatal side effect of bone marrow and stem cell transplants.

 Pictured: Cancer cell on blood vessel
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, February 27, 2014

Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there.

Pictured: Renier Brentjens, Isabelle Rivière & Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, February 20, 2014

A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.

Pictured: Jedd Wolchok & Alexander Rudensky
Announcement
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, January 6, 2014

Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.

Pictured: T cells
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 23, 2013

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

Pictured: Alexander Rudensky
Profile
By Celia Gittelson, BA  |  Monday, December 16, 2013

Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the News
By Christina Pernambuco-Holsten, MA, Managing Web Editor  |  Friday, December 6, 2013

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

Mouse glioblastoma tumor with phagocytic macrophages
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, October 15, 2013

Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.

Pictured: Pseudomonas aeruginosa
Snapshot
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, October 1, 2013

Memorial Sloan Kettering researchers have discovered how a common bacterium can evolve to become more mobile and easier to get rid of.

Pictured: Clostridium difficile
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, August 7, 2013

Information about the microbiome, the genes of all the microorganisms that naturally inhabit the human body, is leading to new approaches for treating infections in cancer patients.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Liang Deng
Profile
By Jim Stallard, MA, Writer/Editor  |  Friday, April 26, 2013

Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Center News

Stay Informed

Get the latest information about cancer care and research every month.